Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linaclotide - Ironwood Pharmaceuticals

Drug Profile

Linaclotide - Ironwood Pharmaceuticals

Alternative Names: ASP-0456; ASP-456; Constella; Linaclotide acetate; Linzess; MD-1100; MD-7246; MM-416775

Latest Information Update: 07 Dec 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Microbia
  • Developer AbbVie; Astellas Pharma; AstraZeneca; Ironwood Pharmaceuticals
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Non-opioid analgesics; Oligopeptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Preclinical Visceral pain

Most Recent Events

  • 11 Oct 2020 Adverse events and therapeutics data from a phase II trial in Irritatble bowel syndrome presented at the 28th United Europen Gastroenterology Week
  • 28 May 2020 Efficacy and safety data from phase II trial in Irritable bowel syndrome with diarrhoea (IBS-D) released by Ironwood Pharmaceuticals
  • 28 May 2020 Ironwood Pharmaceuticals and AbbVie plans to discontinue the development of MD 7246 in for Irritable Bowel Syndrome with diarrhoea (for relief of abdominal pain)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top